InflaRx, a biopharmaceutical company domiciled in Jena, which develops innovative therapies for regulating the complement system, has raised EUR 31 million (USD 34 million) as part of a Series C financing round. The means gained in the financing round will be utilized in the further clinical phase II development of IFX-1 (antibody) for the treatment of various acute and chronic inflammatory diseases. Furthermore, the proceeds will be used for continuing the pre-clinical development of the subsequent molecules of the product pipeline.
In addition to the current investors (among others bm|t as up to now the leading investor), Staidson Hongkong Investment Company Ltd. as well as international industrial investors and family offices participated in the financing.
bm|t, domiciled in Erfurt, is a subsidiary of Thüringer Aufbaubank and currently manages nine funds with a total volume of about EUR 340 million, which participate in innovative companies of almost all industries and at all stages of the development of the companies.
The Corporate Finance team of GRUENDELPARTNER regularly advises financial investors such as bm|t on equity and mezzanine financing transactions, in particular on expansion financing and venture capital / private equity transactions.
- GRUENDELPARTNER: Dr. Mirko Gründel (Lead), Dr. Steffen Fritzsche, Theresa Thümmler (all Corporate)